Related Experiment Video
Updated: Jul 20, 2025

06:36
3D Printed Porous Cellulose Nanocomposite Hydrogel Scaffolds
Published on: April 24, 2019
9.6K
Nanocellulose-Based Film-Forming Hydrogels for Improved Outcomes in Atopic Skin
Katarina Bolko Seljak1, Barbara Sterle Zorec1, Mirjam Gosenca Matjaž1
1Faculty of Pharmacy, University of Ljubljana, Aškerčeva cesta 7, 1000 Ljubljana, Slovenia.
Pharmaceutics
|July 29, 2023
Summary
Novel hydrogels using nanocrystalline cellulose show promise for treating atopic dermatitis (AD). These film-forming systems deliver betamethasone dipropionate effectively, offering a protective barrier for compromised skin.
Area of Science:
- Materials Science
- Pharmaceutical Sciences
- Dermatology
Background:
- Atopic dermatitis (AD) is a chronic inflammatory skin condition.
- Impaired skin barrier function is a hallmark of AD.
- Hydrogels offer potential as film-forming systems for AD treatment, providing a physical barrier.
Purpose of the Study:
- To develop novel film-forming hydrogels for atopic dermatitis treatment.
- To incorporate betamethasone dipropionate (BDP) into hydrogel formulations.
- To evaluate the efficacy of nanocrystalline cellulose (NCC)-based hydrogels as a drug delivery system.
Main Methods:
- Development of hydrogels using nanocrystalline celluloses (NCCs) combined with alginate or pectin.
- Dissolution of betamethasone dipropionate (BDP) using a self-microemulsifying drug delivery system (SMEDDS) with Kolliphor® EL/Capryol® 90.
- Preparation of films via solvent evaporation and in vitro assessment of water retention capacity.
Main Results:
- Successfully developed NCC-based film-forming hydrogels.
- Achieved stable dissolution of BDP within the hydrogel matrix using SMEDDS.
- Demonstrated high water retention capacity of the hydrogel films in vitro.
Conclusions:
- NCC-based film-forming hydrogels are a promising drug delivery system for atopic dermatitis.
- These hydrogels provide a physical barrier and effectively deliver BDP.
- The developed system addresses the need for advanced therapeutic approaches in AD treatment.

